Literature DB >> 20056675

Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.

Chun-Hua Dai1, Jian Li, Shun-Bing Shi, Li-Chao Yu, Li-Ping Ge, Ping Chen.   

Abstract

OBJECTIVE: Survivin and livin, which are members of the inhibitor of apoptosis protein family, regulate both programmed cell death and proliferation. Second mitochondria-derived activator of caspase is thought to regulate apoptosis by antagonizing inhibitor of apoptosis protein. These gene expressions are regarded as prognostic markers in some malignancies. However, result in previous studies of the association of these gene expressions with prognosis of patients with non-small cell lung cancer remains contradictory.
METHODS: Survivin, livin and second mitochondria-derived activator of caspase mRNA was detected by semi-quantitative reverse transcriptase-polymerase chain reaction in surgical resected tumor specimen from 66 non-small cell lung patients who received adjuvant platinum-based chemotherapy.
RESULTS: Results showed that patients with survivin high expression had significantly shorter tumor-free survival (P = 0.012) and overall survival (P = 0.007) than those with survivin low expression. There was a significant association of second mitochondria-derived activator of caspase high expression in non-small cell lung cancer tissue with longer tumor-free survival (P = 0.021) and overall survival (P = 0.0013). However, livin mRNA expression level had no impact on the tumor-free survival and overall survival of the patients. In multivariate analyses, survivin mRNA high expression (P = 0.033 and P = 0.024) and advanced pathologic stage (P = 0.009 and P = 0.008) were the factors which independently predicted a worse tumor-free survival and overall survival.
CONCLUSIONS: Our data suggest that assessment of survivin and second mitochondria-derived activator of caspase mRNA expression may be useful for predicting survival in non-small cell lung cancer patients receiving platinum-based chemotherapy after surgical resection and can provide valuable information for deciding better therapy strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056675     DOI: 10.1093/jjco/hyp165

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  18 in total

1.  Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer.

Authors:  Wei-Lin Shi; Jian Li; Quan-Lei Bao; Jian-Nong Wu; Li-Ping Ge; Li-Rong Zhu; Yi Wang; Wen-Fang Zhu
Journal:  Med Oncol       Date:  2014-02-23       Impact factor: 3.064

2.  Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer.

Authors:  Yi-Ming Hu; Jing Li; Li-Chao Yu; Shun-Bing Shi; Yong-Jie Du; Jian-Nong Wu; Wei Lin Shi
Journal:  Pathol Oncol Res       Date:  2014-07-01       Impact factor: 3.201

3.  Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer.

Authors:  Jianwen Wang; Xiaodong Zhang; Ping Wei; Junhui Zhang; Yinong Niu; Ning Kang; Yuxiang Zhang; Weili Zhang; Nianzeng Xing
Journal:  World J Urol       Date:  2014-03-05       Impact factor: 4.226

4.  Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients.

Authors:  Yong-Jie Du; Jian Li; Wen-Fang Zhu; Yan Wu; Xin-Ping Tang; Yi Wang; Yi-Ming Hu
Journal:  Tumour Biol       Date:  2014-01-05

5.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.

Authors:  Li-Nian Huang; Dong-Sheng Wang; Yu-Qing Chen; Cheng-Ling Zhao; Bei-Lei Gong; An-Bang Jiang; Wei Jia; Feng-Dan Hu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

6.  Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chou-Chin Lan; Chih-Hsin Lee; Err-Cheng Chan; Kuei-Tien Chen
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

7.  Effect of Second mitochondria-derived activator of caspase in combination with Docetaxel on lung cancer cell A549.

Authors:  Xiao-Mei Li; Yong-Wei Yang; Xiao-Kaiti Maimaitiyiming; Cheng-Yu Jin; Wen Zou; Yu-Hua Jiang; Chuan-Liang Peng
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis.

Authors:  J Li; Z-N Li; L-C Yu; S-B Shi; L-P Ge; J-R Wu; Y-M Hu
Journal:  Clin Transl Oncol       Date:  2013-02-12       Impact factor: 3.405

Review 9.  Monitoring survivin expression in cancer: implications for prognosis and therapy.

Authors:  Rodrigo Santa Cruz Guindalini; Maria Cecília Mathias Machado; Bernardo Garicochea
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

10.  Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells.

Authors:  Yan-Fang Tao; Jun Lu; Xiao-Juan Du; Li-Chao Sun; Xuan Zhao; Liang Peng; Lan Cao; Pei-Fang Xiao; Li Pang; Dong Wu; Na Wang; Xing Feng; Yan-Hong Li; Jian Ni; Jian Wang; Jian Pan
Journal:  BMC Cancer       Date:  2012-12-26       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.